Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a Series A+ financing round led by LongRiver Investments. The funding round also saw participation from Zhaode Investment, Zhongqi Capital, BioTrack Capital, and Lilly Asia Ventures. The company plans to utilize the proceeds to accelerate its lead siRNA metabolism pipelines towards global development and to enhance its extrahepatic delivery platform for applications in the central nervous system (CNS) and other therapeutic areas.
Rona Therapeutics specializes in developing therapies for metabolic diseases and CNS degenerative diseases. The company’s proprietary extrahepatic delivery platform is designed to address unmet needs in treating conditions such as amyotrophic lateral sclerosis and Alzheimer’s disease, where current treatment options are limited.- Flcube.com
